Resverlogix Corp. (TSX: RVX), a Calgary-based late-stage biotechnology company, has announced the publication of two new peer-reviewed scientific journal articles examining the biological mechanisms by which its lead clinical candidate, apabetalone, may prevent heart failure. The studies, published in Biomedicines and Biomedicine & Pharmacotherapy respectively, offer fresh insight into apabetalone's potential to reduce metabolic dysfunction and limit cardiac scarring. Investors tracking the company's cardiovascular pipeline may view these publications as meaningful scientific support for apabetalone's clinical profile.

Key Points

  • Resverlogix Corp. (TSX: RVX) is a Calgary-based epigenetics biotechnology company developing apabetalone for cardiovascular disease and associated conditions.
  • Two peer-reviewed journal articles on apabetalone's heart failure prevention mechanisms were published simultaneously in September 2026.
  • One study demonstrated a beneficial metabolic shift and reduced liver fat accumulation in obese mice; the other found reduced cardiac fibroblast activation and scar tissue formation.
  • Investors may be watching how these findings support apabetalone's FDA Breakthrough Therapy Designation and potential next steps in its cardiovascular programme.

Apabetalone's Metabolic Effects on Liver Fat and Heart Failure Markers

The first article, published in Biomedicines and led by Resverlogix researcher Laura Tsujikawa, examined apabetalone's effects in a diet-induced obesity mouse model. Researchers reported that apabetalone drove a metabolic shift towards ketogenesis, increasing circulating ketone levels while reducing lipid accumulation in the liver. The study also found lowered levels of NT-proBNP, a recognised diagnostic marker of heart failure. The company states these findings introduce a potential rationale for apabetalone's use in treating fatty liver disease, in addition to its established cardiovascular focus.

Cardiac Fibrosis Suppression Aligns With BETonMACE Hospitalisation Data

The second article, published in Biomedicine & Pharmacotherapy and led by Dr. Sylwia Wasiak and Dr. Dean Gilham, investigated apabetalone's role in cardiac fibrosis. Following cardiac injury, excessive extracellular matrix deposition by cardiac fibroblasts can impair the heart's mechanical function. The researchers found that apabetalone treatment reduced cardiac fibroblast activation and their deposition of extracellular matrix. The company notes these findings align with the reduction in heart failure hospitalisations observed among apabetalone-treated patients in its Phase 3 BETonMACE clinical study.

Apabetalone's Regulatory Standing and Clinical Safety Record

Apabetalone (RVX-208) holds Breakthrough Therapy Designation from the U.S. Food and Drug Administration for a major cardiovascular indication, awarded following BETonMACE Phase 3 results. The release states apabetalone is the only drug in its class considered well tolerated for chronic administration, with a safety record spanning multiple human clinical trials totalling over 4,200 patient-years of data. As a BD2-selective BET inhibitor, it operates through an epigenetic mechanism, simultaneously targeting multiple disease-related biological processes.